 |
|||||
|
|
|||||
 |
|||||
|
|
|||||
|
|
|||||
|
|
|||||
|
|
|||||
|
|
|||||
|
|
|||||
|
|
|
|
|
||||
|
|
|
|
|
||||
| 7:00am - 8:30am | Registration, Welcome Coffee & "Visit the Exhibits" |
| 8:30am | Opening Remarks, Mr. Clyde Payn, The Catalyst Group |
| 8:45am | Challenges of Fine Chemicals Industry, Dr. David Killworth, Avecia Fine Chemicals |
| 9:30am | Combinatorial Screening of Catalysts: Opportunities for Maximizing Variation in Catalyst Screening, Dr. Duncan Akporiaye, SINTEF Applied Chemistry |
| 10:10am-10:40am | Morning Break & "Visit the Exhibits" *Morning Break Sponsored by Degussa* |
| 10:40am | How Predictable is Asymmetric Hydrogenation Chemocatalysis?, Dr. Ray McCague, Dow Custom and Fine Chemicals (ChiroTech) |
| 11:20am | Powerful New Manufacturing Technologies for Chiral Molecules, Dr. John Blacker, Avecia Pharmaceuticals |
| 12:00pm | An European Overview of the Pharmaceutical Market, Mr. Simon Thompson, IMS Health |
| 12:40pm-2:00pm | Group Luncheon |
| 2:00pm | Efficient Synthesis of Merck's NK1 Receptor Antagonist Dr. Joseph Armstrong, Merck & Co., Inc. |
| 2:40pm | An Industrial Process to Control a Potentially Hazardous Reaction: Conversion of Aryl 1,1-Dimethylpropargyl Ethers to 2,2-Dimethylchromenes (2,2-Dimethyl-2H-1-Benzopyrans), Dr. N. Soundararajan, Bristol-Myers Squibb Company |
| 3:20pm-3:50pm | Afternoon Break & "Visit the Exhibits" |
| 3:50pm | Synthesis of Enantiopure Amines using Biocatalysis Dr. Rinus Broxterman, DSM Research |
| 4:30pm-5:15pm | Special Feature - Round Table Discussion Recent Issues Affecting Speed to Market - Q&A with brief overviews of issues Panel comprised of 4-5 pharmaceutical industry participants |
| 5:30pm-7:00pm | Group Reception |
PLEASE NOTE: This program is accurate as of press time; substitutions may be required in the case of illness or other unforeseen circumstances. The Catalyst Group reserves the right to make these changes.
|
|
|||
|
|
|||
|
|
|||